Meeting requirements for over-the-counter (OTC) medicines containing loperamide hydrochloride

This monograph only applies to medicines containing loperamide hydrochloride (CAS no. 34552-83-5) and excludes preparations containing any other salts and derivatives of loperamide.

Acceptable dosage forms and strengths are shown in the table below.

Required therapeutic indications for inclusion in the Australian Register of Therapeutic Goods

Symptomatic treatment of acute non-specific diarrhoea.

Label indications

The following label indications/claims are acceptable:

• 'Diarrhoea relief'
• 'Effective relief of/from diarrhoea'
• 'Symptomatic relief of/from diarrhoea'
• Reference to 'loose motions'
• 'Relief within 1-3 hours'

 Note: Reference to 'fast', 'rapid' or similar is not acceptable.

Adults and children 12 years and over: 2 tablets/capsules initially, followed by 1 tablet after each loose motion, to a maximum of 8 tablets/capsules per day.

Do not give to children under 12 years of age.¹

Labelling must comply with all relevant Australian regulatory requirements, as detailed in the document Requirements for OTC new medicine N2 applications, including all required warning statements.

Advisory statements

The following advisory statements are required:²

• If the condition persists after two days of treatment, seek medical advice as soon as possible.
• If you are pregnant or breastfeeding, check with your doctor or pharmacist before using this medicine.³
• Drink plenty of fluids as fluid and electrolyte depletion may occur with diarrhoea. If dehydration is suspected seek medical attention.
• Do not take if you have a medical condition where constipation should be avoided.
• See your doctor or pharmacist before taking [this medicine/insert name of medicine] if you have a fever, severe stomach pain, bloody diarrhoea or ongoing condition affecting the bowel.

In addition to the quality requirements outlined in the document Requirements for OTC new medicine N2 applications, the following specific requirements apply to loperamide hydrochloride monograph medicines:

Manufacture

If the total weight of the tablet or capsule exceeds 100 mg (i.e. active ingredient is less than 2% w/w of the dosage form), the manufacturing process must have been validated on a minimum of two production batches in accordance with the requirements of GMP, prior to submission of the application⁴. An assurance that this has been done must be provided with the application.

Finished product specifications

In addition to other requirements specified in the document Requirements for OTC new medicines N2 applications, the finished product specifications must comply, at a minimum, with the relevant set of requirements below.

The requirements below include all relevant BP general monograph/USP General Chapter requirements and TGO78 requirements. Further reference to these is not required.

References to pharmacopoeial monographs below refer to the current monograph at time of application.

Tablets

The tests and limits in the USP monograph Loperamide Hydrochloride Tablets with the addition of:

• tablet appearance
• tighter limits for loperamide hydrochloride content of 92.5-107.5% (in accordance with TGO 78)
• Loperamide N-oxide (NMT 2% wrt loperamide hydrochloride)⁵
• microbiological quality, in compliance with TGO 77

Capsules

The tests and limits in the BP monograph Loperamide Capsules⁶ with the addition of:

• capsule appearance
• microbiological quality, in compliance with TGO 77

Container/measuring device

If a measuring device is to be supplied with the product, calibrations must be exclusively in metric units and must allow all the doses shown on the labels to be measured accurately.

Details of the calibrations on the measuring device must be provided with the submission (a sample may also be requested). 

Further considerations and requirements regarding measuring devices are detailed in ARGOM Appendix 2: Guidelines on quality aspects of OTC applications, 8. Finished product container.

1. This is a RASML statement.
2. The above advisory statements are included in RASML Schedule 2.
3. This statement will be revised pending a final outcome on a RASML consultation to change the pregnancy and breastfeeding warning statement for loperamide.
4. In accordance with manufacturing process validation requirements for 'microdose' products, as detailed in section 5.2.1 of Appendix 2 of the ARGOM
5. Use assay method specified for Loperamide Hydrochloride Capsules BP, or an alternative equivalent or superior method. The method must be appropriately validated as described in Requirements for OTC new medicine N2 applications.
6. Including dissolution test, with a limit of NLT 70% in 45 min, in accordance with Appendix XII B. Monographs of the British Pharmacopoeia.